FDA approves treatments for two rare blood diseases
On Dec. 21, the FDA approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria and approved Elzonris (tagraxofusp-erzs) infusion…
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.